Мукозальные вирусные вакцины: успехи и проблемы


Цитировать

Полный текст

Аннотация

Представлены данные, полученные в последние годы, по разработке вирусных инактивированных мукозальных вакцин с использованием мукозоадгезивных адъювантов. Отмечены успехи в разработке мукозальных гриппозных вакцин и мукозальных вакцин против ряда других вирусных инфекций. При интраназальном применении вирусных мукозальных вакцин наблюдается кроссзащита против вариантов вируса в пределах подтипа, а также преодоление негативного влияния материнских антител на иммуногенность живых вакцин, применяемых в раннем возрасте. Отмечаются определенные недостатки бактериальных токсинов, применяемых в качестве мукозоадгезивных адъювантов, а также проблемы, которые могут возникнуть при массовом применении вирусных мукозальных вакцин из-за необходимости их двух-, трехкратного интраназального применения.

Список литературы

  1. Гендон Ю. 3. Вирусные мукозальные вакцины // Вопр. вирусол. - 1999. - № 3. - С. 100-105.
  2. Гендон Ю. 3. Разработка мукозальных гриппозных инактивированных вакцин // Журн. микробиол. - 2003. - № 3. - С. 98-103.
  3. Alexandrova G., Potezhaev F., Budilovsky G. et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vacinees // Infect. and Immun. - 1984. - Vol. 44. - P. 734-739.
  4. Azakura Y., Landhalm P., Kiersslrom A. et al. DNA-plasmids of HIV-1 induce systemic and mycosal immune responses // J. Biol. Chem. - 1999. - Vol. 380. - P. 375-379.
  5. Belshe R., Mendelman P., Treanor M. et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children // N. Engl. J. Med. - 1998. - Vol. 338. - P. 1405-1412.
  6. Bergsquist C., Johansson E., Lagergard T. et al. Intranasal vaccination of humans with recombinant cholera toxin В subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina // Infect. and Immun. - 1997. - Vol. 65. - P. 2676-2684.
  7. Beyer W., Palache A., de Jong J. et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A metaanalysis // Vaccine. - 2002. - Vol. 20. - P. 1340-1353.
  8. Bruhl P., Kerschbaum A., Eibl M. et al. An experimental primeboost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice // AIDS Res. Hum. Retrovirus. - 1998. - Vol. 14. - P. 401-407.
  9. Bryant M., Brown P., Gurvich N. et al. Comparison of the clearance of radiolabeled nose drops and nasal spray as mucally delivered vaccine // Nucl. Med. Commun. - 1999. - Vol. 20. - P. 171-174.
  10. Cheng E., Cardenas-Freytag L., Clements J. The role of cAMP in mucosal adjuvanticity of E. coli heat-labile enterotoxin (LT) // Vaccine. - 2000. - Vol. 18. - P. 38-49.
  11. Coste A., Sirard J., Johansen K. et al. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea // J. Virol. - 2000. - Vol. 74. - P. 8966-8971.
  12. Couch R., Quarks J., Cate T. et al. Clinical trials with live coldreassortant influenza vaccines // Options for the Control of Influenza. - New York, 1986. - P. 223-241.
  13. Davis S., Ilium L., Gill J. et al. Polymer lamellar particles as a novel adjuvant for influenza vaccines // Options for the Control of Influenza IV. - Crete, Hersonossis, 2000. - Abstr. W62-1. - P. 50.
  14. De Haan L., Willem R., Noltrop M. et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the В subunit of E. coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity // Vaccine. - 2001. - Vol. 19. - P. 2898-2907.
  15. Del Guidece G., Rappuoli R. Genetically derived toxoids for use as vaccines and adjuvants // Ibid. - 1999. - Vol. 17. - P. 44-52.
  16. Dupuy C., Bizoni-Gatel D., Touze A. et al. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 LI gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes // J. Virol. - 1999. - Vol. 73. - P. 9063-9071.
  17. Ferco В., Katinger D., Grassauer A. et al. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract // J. Infect. Dis. - 1998. - Vol 178. - P. 1359-1368.
  18. Gerber S., Lane C., Brown D. et al. Human papillomavirus viruslike particles are efficient oral immunogens when coadministered with E. coli heat-labile enterotoxin mutant R192G or CpG DNA // J. Virol. - 2001. - Vol. 75. - P. 4752-4760.
  19. Gliick U., Gebbers J., Gliick R. Phase I evaluation of intranasal virosomal influenza vaccine with and without E. coli heat-labile toxin in adult volunteers // Ibid. - 1999. - Vol. 73. - P. 7780-7786.
  20. Goetsch L., Gonzales A., Plotnicky H. et al. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae // Infect. and Immun. - 2001. - Vol. 69. - P. 6434-6444.
  21. Goetsch L., Plotnicky H., Aubry J. et al. BBG 2Na an RSV subunit vaccine candidate intramuscularly injection to human confers protection against vital challenge after nasal immunization in mice // Vaccine. - 2001. - Vol. 19. - P. 4036-4042.
  22. Hashigucci K., Ogawa H., Ishidate T. et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with E. coli heat-labile enterotoxin В subunit containing a trace amount of holotoxiik // Ibid. - 1996. - Vol. 14. - P. 113-119.
  23. Huang Y., Anderson R. Enhanced immune protection by a lyposome-encapsulated recombinant RSV vaccine using immunogenic lipms from Deinococcus radiodurans // Ibid. - 2002. - Vol. 20/- P. 1586-1592.
  24. Illum L., Jabal-Gill I., Lin W. et al. The immune response of nasally administered influenza vaccine is enhanced by the polysaccharide chitosan // Options for the Control of Influenza IV. - Crete, Hersonossis, 2000. - Abstr. W62-3. - P. 50.
  25. Illum L., Jabbal-Gill I., Hincheliffe M. et al. Chitozan as novel nasal delivery system for vaccines // Adv. Drug Delivery Rev. - 2001. - Vol. 51. - P. 81-96.
  26. Johnson P., Feldman S., Thompson J. et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine // J. Infect. Dis. - 1986. - Vol. 154. - P. 121-127.
  27. Kang D., Kim P., Ко E. et al. Peroral immunization of microcapsulated human VP8 in combination with cholera toxin induces intestinal antibody responses // Mol. Cells. - 1999. - Vol. 9. - P. 609-616.
  28. Kawana K., Kawana Y., Yoshikawa H. et al. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies // Vaccine. - 2000. - Vol. 19. - P. 1496-1502.
  29. Komase K., Tamura S., Matsuo К. et al. Mutants of E. coli heatlabile enterotoxin as an adjuvant for nasal influenza vaccine // Ibid. - 1998. - Vol. 16. - P. 348-254.
  30. Kozlowski P., Cu-Uvin S., Neutra M. et al. Comparison of the oral rectal and vaginal immunization routes for induction of antibodies in rectal and genital tract secretion of women // Infect. and Immun. - 1997. - Vol. 65. - P. 1387-1394.
  31. Kozlowski P., Cu-Uvin S., Neutra M. et al. Mucosal vaccination strategies for women // J. Infect. Dis. - 1999. - Vol. 179. - Suppl. 3. - P. S493-S498.
  32. Lambert J., Keefer M., Milligan M. et al. A phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects // Vaccine. - 2001. - Vol. 19. - P. 3033-3042.
  33. Liashenko V., Krasnova V., Youminova N. Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measled vaccine L-16 // Hum. Antibodies. - 1999. - Vol. 9. - P. 143-148.
  34. MacDonald M., Li X., Stenberg R. et al. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus infection by using an attenuated mutant // J. Virol. - 1998. - Vol. 72. - P. 442-451.
  35. Mutwiri G., Bateman C., Baca-Estrada M. et al. Induction of immune responses in newborn lambs following enteric immunization with a human adenovirus vaccine vector // Vaccine. - 2000. - Vol. 19. - P. 1284-1293.
  36. Nardelli-Haefinger D., Roden R., Balmelli C. et al. Mucosal but not parenteral immunization with purified human papilomavirus type 16 virus-like particles induces neutralising titers of antibodies throughout the esterous cycle of mice // J. Virol. - 1999. - Vol. 73. - P. 9609-9613.
  37. Niewiesk S. Studing experimental measles virus vaccines in the presence of maternal antibodies in the cotton rat model (Sigmodon hispidus) // Vaccine. - 2001. - Vol. 19. - P. 22502253.
  38. Oien N., Brideau R., Walsh E. et al. Induction of local and systemic immunity against human respiratory syncitial virus using a chimeric FG glycoprotein and cholera toxin В subunit // Ibid. - 1994. - Vol. 12. - P. 731-735.
  39. O'Neal C., Clements J., Estes M. et al. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, E. coli heat-labile toxin (LT), and LT-R1926 induce protection from rotavirus challenge // J. Virol. - 1998. - Vol. 72. - P. 33903393.
  40. Plante M., Jones D., Allard F. et al. Nasal proteosome subunit flu vaccine elicits enhance mucosal IgA, serum HAI and protection comparable to conventional injectable flu vaccine // Options for the Control of Influenza IV / Eds A. Osterhaus et al. - Amsterdam, 2001. - P. 979-984.
  41. Plante M., Jones D., Allard F. et al. Nasal immunization with subunit proteosome influenza vaccine induces serum HAI, mucosal IgA and protection against influenza challenge // Vaccine. - 2002. - Vol. 20. - P. 218-225.
  42. Rapp Z., Middleton D., Mittal S. et al. Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection // J. Gen. Virol. - 1997. - Vol. 78. - P. 2933-2943.
  43. Rapp Z, Babik L., Baca-Estrada M. The effect of pre-existing adenovirus-specific immunity on immune response induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1 // Vaccine. - 1999. - Vol. 17. - P. 933-943.
  44. Rudenko L., Slepushkin A., Monto A. et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia // J. Infect. Dis. - 1993. - Vol. 168. - P. 881-887.
  45. Sanz-Parra A., Vazquez В., Sobrino F. et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (PI) of foot-and-mouth disease virus capsid proteins // J. Gen. Virol. - 1999. - Vol. 80. - P. 671-679.
  46. Sazaki S., Sumino K., Hamajima K. et al. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes // J. Virol. - 1998. - Vol. 72. - P. 4931-4939.
  47. Schmidt A., McAuliffe J., Murphy B. et al. Recombinant bovine/ human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3 // Ibid. - 2001. - Vol. 75. - P. 4594-4603.
  48. Siadat-Pajouh M., Cai L. Protective efficacy of rotavirus 2/6virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant // Viral Immunol. - 2001. - Vol. 14. - P. 31-47.
  49. Stokes C., Finerty S., Graffydd-Jones T. et al. Mucosal infection and vaccination against feline immunodeficiency virus // J. Biotechnol. - 1999. - Vol. 73. - P. 213-221.
  50. Tang S., van Rij R., Silvera D. et al. Towards a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity // J. Virol. - 1997. - Vol. 71. - P. 7841-7850.
  51. Tebbey P., Unczur C., LaPierre N. et al. A novel and effective intrfanasal immunization strategy for respiratory syncytial virus // Viral Immunol. - 1999. - Vol. 12. - P. 41-45.
  52. Velin D., Hopkins S., Krachenbuhl J. Delivery systems and adjuvants for vaccination against HIV // Pathobiology. - 1998. -Vol.66. -P. 170-175.
  53. Welter J., Taylor J., Tartaglia J. et al. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines // J. Virol. - 2000. - Vol. 74. - P. 6358-6367.
  54. Yuan L., Geyer A., Hodgins D. et al. Intranasal administration of 2/6-rotavirus-like particles with mutant E. coli heat-labile toxin (LT-R192G) induces antibody-secreting cell response but not protective immunity in gnotobiotic pigs // Ibid. - 2000. - Vol. 74. - P. 8843-8853.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Гендон Ю.З., 2003

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах